Drug intelligence / Profile preview

APT-0001P

Development stage: Preclinical
Lead developer: Aptah Bio
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

APT-0001P is an investigational RNA therapy developed by Aptah Bio for the treatment of glioblastoma (GBM). It utilizes the proprietary RNA WiCo™ platform to target the U1 small nuclear ribonucleoprotein (U1 snRNP). The mechanism of action involves modulating RNA splicing and processing, which are critical pathways often hijacked in aggressive brain tumors like glioblastoma. As of early 2024, the candidate is in the IND-enabling phase of development.

Beyond the preview

Go deeper on APT-0001P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APT-0001P.

Explore the full profile